Pat Adams

Product Development New England, Naveris, NavDx, minimal residual disease monitoring in head and neck cancer

[Pat Adams @PathologyPat]

Deep learning-based non-invasive profiling of tumor transcriptomes from cell-free DNA for precision oncology | bioRxiv https://t.co/p5hS4Lir8q

[Pat Adams @PathologyPat]

ERBB2 amplification is a late event in the pathogenesis of high-grade endometrial carcinomas with heterogeneous HER2 expression - PubMed https://t.co/SrK9L3tfbo

[Rockefeller University @RockefellerUniv]

A new study from Rockefeller's Victora lab in @CellCellPress reveals how germinal centers produce powerful antibodies through noisy rounds of mutation and selection, offering new insight into vaccine design—and larger themes in evolution.

🔗: https://t.co/asRL8NPIXZ

[Clinical Cancer Research @CCR_AACR]

Now online: Combinatorial Delivery of Low-Dose Radiotherapy and Immunotherapy to Patients with Immune-Excluded Tumors Enhances CD8 + T-cell Functionality https://t.co/w4kYrywxhv

[The Journal of Molecular Diagnostics @JMDiagn]

#LegacyContent: Comparison of targeted RNA sequencing platforms for oncogenic fusion detection in non-small cell lung cancer. From @AMPath member author Dr. James P. Solomon and colleagues from @WCMCPathology and @WeillCornell.

#OpenAccess text: https://t.co/u899N519QB

[Cell Reports @CellReports]

FGF21 suppresses hepatocellular carcinoma by driving competitive cell-cell interactions https://t.co/E4sf1IdPiR

[Pallawi Torka @PallawiTorkaMD]

A compilation of top lymphoma/CLL abstracts from #EHA2026 by @lymphomahub steering committee.

Looking forward to some great data.
@chanyooncheah @Dr_KatLewis @tobyeyre82 @WomenInLymphoma @KrishPatelMD @elizabeth_budde @StefanoLuminari

[Sanam Loghavi, MD صنم لغوی 🔬🧬 @sanamloghavi]

A must read for all hematopathologists and heme molecular pathologists congratulations to @DrChrisHourigan and team on this very important publication
@BloodPortfolio

https://t.co/Slbi8to8um

[Human Pathology @Human_Pathology]

New in #HumPathol: The role of advanced molecular diagnostics in informing targeted therapies for AML. https://t.co/Sa2q7qlUS6 #pathology #PathTwitter #PathX #hemepath

[Mali Barbi, MD MSc | Breast & Gyn Oncologist @DrBarbiOnc]

My #ASCO26 #EndometrialCancer recap PART 3. Saving the best for last.

This was the biggest disease area at the meeting. And it delivered.

The headline We have been telling dMMR advanced EC patients we can control their disease. After this week we need to update that conversation to cure.

RUBY at 4.5 years: mixture cure modeling estimates 54% of dMMR/MSI-H patients treated with dostarlimab + carbo/taxol may never recur. 14% with chemo alone. KM curve stopped moving. Only 4 new progression events in 2.5 additional years of follow-up.
NRG-GY018 confirms it independently: 79% vs 60% alive at 48 months in dMMR, HR 0.56. pMMR median OS 44.4 vs 35.1 months. Both benefits held despite 93% and 81% IO crossover in the control arms respectively.

Two independent phase 3 trials. Same conclusion. The crossover argument is officially dead.

The pipeline PuxiSam (B7-H4 ADC): ORR 35-39% in post-platinum post-IO EC. FDA Breakthrough Designation granted. Phase 3 BLUESTAR-Endometrial01 now enrolling. Carcinosarcoma eligible.

Abemaciclib + hormonal therapy: phase 2 signal in recurrent EC. CDK4/6 inhibition in endometrial cancer is early but worth watching.

The bigger picture Endometrial cancer is the most common gynecologic malignancy in the US. It is also the one where outcomes have improved the most dramatically in five years. dMMR disease went from a poor prognosis subtype to a potentially curable one. pMMR still needs better solutions and the field knows it.
My clinical take for tomorrow in clinic:

Every dMMR advanced EC patient starting frontline therapy gets dostarlimab + carbo/taxol. You can now tell them more than half of people in their situation may never recur. That is a different conversation than disease control. Have it.

For pMMR patients progressing after platinum and IO: ask whether B7-H4 testing is available at your institution and whether BLUESTAR-Endometrial01 is open at your site. Carcinosarcoma is eligible. This is the most important open EC trial right now for that population.
The week is done. Endometrial cancer had a very good meeting in Chicago.

#ASCO2026 #EndometrialCancer #GynOnc #EndoCancer
@ASCOPost @NRGonc @SGO_org

[Busra YAPRAK BAYRAK @byrk_bsr]

Happy to share our new publication. A study exploring HPV-DNA&p16INK4a expression in prostate cancer patients diagnosed at ≤55 y of age
https://t.co/38d0wwQVKA
https://t.co/e1YMZ1RJeD

@IntSocUropath @GU_Path_Society
#GUpath #ProstateCancer #UrologicOncology

[Swikrity U Baskota,MD, FCAP,FASCP @Baskotacytopath]

Read this interesting entity in 🫁 EWSR::CREM Fusion! Fresh out of press in Diagnostic Cytopathology ! Thankful for the collaborative work on this with @smlungpathguy @priya_upa cc: @aakasharmand @PoonamVohra3 @GokozanMD @PapSociety

https://t.co/vBd1BLEIQB

[IJGC @IJGConline]

Pre-operative #PETscan is associated with lower rates of adjuvant treatment in surgically treated patients with #cervicalcancer

📉 Lowering the treatment burden
🎯 Better patient selection
🛡️ Improving quality of life

📌 https://t.co/d5wHXaniZl

@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @ElePanizzolo @esragbilir @ChiaraAinio @alicezampolini @Chiara_4997 @Lawalqdus @kamillaldavid @Dra_AnaConde

[Human Pathology @Human_Pathology]

New in #HumPathol: Radiological over- and underestimation of DCIS extent in breast conserving surgery specimens: rad-path correlation in slice radiographs and respective histological large-format slides. https://t.co/3qO1R87QgN #pathology #PathTwitter #PathX #breastpath

[Global Society of Rare Genitourinary Tumors @GTumors]

Rare RCC is not one disease — it is an entire spectrum of biologically distinct tumors with unique molecular drivers. 🧬

Phenomenal review from the @cityofhope team describing the evolving molecular landscape of rare RCC and the urgent need for subtype-specific research and precision medicine approaches.

A must read for anyone interested in kidney cancer!

@ESadimin @ActuallyGZhang @montypal @CityofHope_GU @SpiessPhilippe @drgaganprakash @LuisMedinaMD @npaesa @CMercinelli @dramandeeparora @CurtisPettaway1 @MDAndersonNews @MoffittNews @TataMemorial @AmerUrological @UroOnc @SUO_YUO @CAU_URO @AndreaNecchi @EauPatient @JadChahoud @PGrivasMDPhD @herneygarcia

[Springer Pathology @SpringerPath]

Virchows Archiv outlines the critical role of tissue biobanking in biomedical research, emphasizing the need for standardized procedures to ensure sample quality and reproducibility in research outcomes.

https://t.co/hoqguYQdHd

[Dr. Anthony Letai @NCIDirector]

Fresh off of #ASCO26, I'm compelled to share more about how NCI-funded research fuels progress. Our #YourNCI initiative describes how @theNCI—through critical funding and hands-on science across the cancer continuum—advances research, leading to better outcomes for patients.

[Frida Rosenblum @FridaRosenblum]

Where do I find all the Cytopathology fellowship match information I need? On the ASC website! Check out this video. @cytopathology @DivaRSalomao #match #education #cytology #fellowship

[andi roy @andiroy]

New paper from lab: many congratulations to Rebecca, Alia and Lucy who led this work. And many thanks to all collaborators and funders. @OxPaediatrics @MRC_WIMM @OxfordCancer #infantALL https://t.co/Q64DQX0T5d

[Evgenii Protasov @protasov_evgeni]

Artificial intelligence in bioinformatics: a survey
#bioinformatics #AI #MachineLearning
https://t.co/xm6sGA5j0E